Quoin Pharmaceuticals Ownership
| QNRX Stock | USD 0.32 0.01 3.03% |
Quoin |
Quoin Stock Ownership Analysis
About 17.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.47. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Quoin Pharmaceuticals recorded a loss per share of 3.66. The entity last dividend was issued on the 23rd of October 2019. The firm had 1:12 split on the 18th of July 2023. Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Quoin Pharmaceuticals, Ltd. was incorporated in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. To find out more about Quoin Pharmaceuticals Ltd contact Michael Myers at 703 980 4182 or learn more at https://quoinpharma.com.Besides selling stocks to institutional investors, Quoin Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Quoin Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Quoin Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Quoin Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
About 17.0% of Quoin Pharmaceuticals Ltd are currently held by insiders. Unlike Quoin Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Quoin Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Quoin Pharmaceuticals' insider trades
Quoin Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Quoin Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Quoin Pharmaceuticals Ltd backward and forwards among themselves. Quoin Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Quoin Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-09-30 | 1.3 K | Sbi Securities Co Ltd | 2024-12-31 | 24.0 | Resources Investment Advisors Inc | 2024-09-30 | 0.0 | Susquehanna International Group, Llp | 2024-09-30 | 0.0 | Two Sigma Investments Llc | 2024-09-30 | 0.0 | Virtu Financial Llc | 2024-12-31 | 0.0 | Bank Of America Corp | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-12-31 | 530 K | Altium Capital Management, Lp | 2024-12-31 | 282.2 K | Ikarian Capital, Llc | 2024-12-31 | 275 K | Renaissance Technologies Corp | 2024-12-31 | 133.1 K |
Quoin Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Quoin Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Quoin Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Quoin Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Myers over three months ago Acquisition by Michael Myers of 5322 shares of Quoin Pharmaceuticals at 0.6558 subject to Rule 16b-3 | ||
Michael Myers over three months ago Acquisition by Michael Myers of 800 shares of Quoin Pharmaceuticals at 0.619 subject to Rule 16b-3 | ||
Langer Dennis over six months ago Disposition of 297 shares by Langer Dennis of Quoin Pharmaceuticals at 0.732 subject to Rule 16b-3 | ||
Denise Carter over a year ago Acquisition by Denise Carter of 80966 shares of Quoin Pharmaceuticals subject to Rule 16b-3 | ||
Cooper Joseph Patrick over a year ago Quoin Pharmaceuticals exotic insider transaction detected |
Quoin Pharmaceuticals Outstanding Bonds
Quoin Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Quoin Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Quoin bonds can be classified according to their maturity, which is the date when Quoin Pharmaceuticals Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Quoin Stock Analysis
When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.